PLB1004, yakozwe na Beijing Avistone Biotechnology Co., Ltd., ni umuti wizewe, utoranya cyane kandi ukora neza utuma tyrosine kinase inhibitor (EGFR-TKI) ikoreshwa mu kuvura kanseri y’ibihaha itari iy’uturemangingo duto (NSCLC).
Ku ya 9 Mata 2025, Ikigo cy’Igihugu gishinzwe Isuzuma ry’Imiti (CDE) cyagaragaje ko PLB1004 ya Beijing Avistone Biotechnology yari igamije gushyirwa mu buvuzi bw’ibanze ku barwayi barwaye kanseri y’ibihaha iteye imbere mu gace runaka cyangwa kanseri y’ibihaha ya METastatic non-small cell (NSCLC) bafite EGFR mutation, bahuye n’izamuka ry’imisemburo cyangwa bakagira ubumuga bwo kunanirwa nyuma yo kunanirwa kwa EGFR-TKI.
Ibisubizo by’ibanze bya PLB1004 hamwe na Vebreltinib mu kuvura abarwayi ba kanseri y’ibihaha batari bazima bafite EGFR mutations, MET amplification cyangwa MET overexpression nyuma ya EGFR-TKI byatangajwe mu nama mpuzamahanga ya 2024 kuri kanseri y’ibihaha.
Abarwayi mirongo ine na bane bahawe Vebreltinib 100mg hamwe na PLB1004 160mg (n=15), Vebreltinib 150mg hamwe na PLB1004 160mg (n=13), Vebreltinib 200mg hamwe na PLB1004 80mg (n=3), cyangwa Vebreltinib 150mg hamwe na PLB1004 80mg (n=13) kandi bashyizwe mu isesengura rusange ry’umutekano. Mu barwayi 44 basuzumwe, 36.4% by’abarwayi bari bafite indwara zo mu bwonko naho 86.4% by’abarwayi bari barahawe EGFR-TKI yo mu gisekuru cya gatatu. Ibisubizo by’intego byagaragaye ku gipimo cya Vebreltinib na PLB1004 byose, hapimwa uburyo bwo gusubiza igice (PRs) ku barwayi bapimwe ibisubizo bya 19/32 (59.4%). Mu barwayi bafite indwara zo mu bwonko, ORR yari 75.0% (9/12). ORR yari 58.6% (17/29) mu barwayi babanje guhabwa EGFR-TKI yo mu gisekuru cya gatatu. TRAE zikunze kugaragara cyane ni urwara rwo mu maso na paronychia. Nta barwayi bahagaritse kuvurwa kubera TRAE.
Kugeza ubu, haracyari igeragezwa ryinshi ry’ikoranabuhanga rishya rirwanya kanseri mu Bushinwa rishaka abarwayi. Inama ku miti mishya n’ikoranabuhanga, ushobora kuvugana n’Ishami Mpuzamahanga ry’Ibitaro bya Oncology bya Beijing mu Karere k’Amajyepfo.
Nimero ya Terefone: 4008803716
Email：myimmnet@163.com
Igihe cyo kohereza: 10 Mata 2025